In agreement with expectations, the first outcome trial of a GLP-1RA, the ELIXA trial of the short-acting lixisenatide, an exendin-4 derivative with properties almost identical to those of exendin-4 or exenatide (stable, full agonists of the GLP-1 receptor), showed no increased cardiovascular risk in a patient group with severely increased CVD risk
Zero Shot 12li L-carnitine 3000 mg 60 mllik ielerde 12 tane shot eklinde sunulan Zero Shot 12li Portakal Aromal L-carnitine 3000 mgn ieriinde yalnzca L-carnitine deil ayn zamanda krom, folik asit, sodyum, malik asit, vitamin B6, vitamin B12, taurin ve kafein de bulunur
Rakipovski G, Rolin B, Nohr J, Klewe I, Frederiksen KS, Augustin R, Hecksher-Sorensen J, Ingvorsen C, Polex-Wolf J, Knudsen LB
Euglycemic Ketoacidosis From Semaglutide in a Patient Without Diabetes
Future directions include: Validation of predictive biomarkers (e.g., A42/A40 dynamics, PVS quantification) Trials comparing ASM effectiveness and tolerability in older adults with PSE Investigation of disease-modifying strategies targeting neurovascular inflammation and glymphatic dysfunction Electroencephalography in poststroke epilepsy Acute epileptiform abnormalities on EEG are independent predictors of poststroke seizures and the subsequent development of PSE [42]
Focus on staying hydrated, eating simple, balanced meals, and letting your body settle into the routine
